Neurelis, Inc.

Neurelis, Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

Neurelis, Inc., is dedicated to innovating life-changing therapeutics that help people with neurological conditions gain greater control over their journeys.

Company Details

Employees
179
Founded
-
Address
3430 Carmel Mountain Rd,
Phone
858-251-2100
Email
in****@****lis.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
San Diego, California
Looking for a particular Neurelis, Inc. employee's phone or email?

Neurelis, Inc. Questions

News

Neurelis to Highlight Data from a Study of Diazepam Nasal Spray in Pediatric Patients at the Child Neurology Society Annual Meeting - PR Newswire

Neurelis to Highlight Data from a Study of Diazepam Nasal Spray in Pediatric Patients at the Child Neurology Society Annual Meeting PR Newswire

Neurelis' nasal spray gains FDA approval for seizure treatment - Pharmaceutical Technology

Neurelis' nasal spray gains FDA approval for seizure treatment Pharmaceutical Technology

NEURELIS ANNOUNCES FDA APPROVAL FOR IMMEDIATE USE SEIZURE MEDICATION VALTOCO® (DIAZEPAM NASAL SPRAY) IN AGES 2 TO 5 - PR Newswire

NEURELIS ANNOUNCES FDA APPROVAL FOR IMMEDIATE USE SEIZURE MEDICATION VALTOCO® (DIAZEPAM NASAL SPRAY) IN AGES 2 TO 5 PR Newswire

A Single-Dose, Randomized, Open-Label, Parallel Design Study to Characterize the Pharmacokinetics of an Investigational Olanzapine Intranasal Spray Compared to a Reference Dose of Olanzapine Intramuscular Injection in Healthy Adult Males - Psychiatrist.com

A Single-Dose, Randomized, Open-Label, Parallel Design Study to Characterize the Pharmacokinetics of an Investigational Olanzapine Intranasal Spray Compared to a Reference Dose of Olanzapine Intramuscular Injection in Healthy Adult Males Psychiatrist.com

Federal Judge Backs Neurelis, Rules FDA Violated Orphan Drug Act - Bloomberg Law News

Federal Judge Backs Neurelis, Rules FDA Violated Orphan Drug Act Bloomberg Law News

Significant improvements in SEIzure interVAL (time between seizure clusters) across time in patients treated with diazepam nasal spray as intermittent rescue therapy for seizure clusters - Misra - 2022 - Epilepsia - Wiley Online Library

Significant improvements in SEIzure interVAL (time between seizure clusters) across time in patients treated with diazepam nasal spray as intermittent rescue therapy for seizure clusters - Misra - 2022 - Epilepsia Wiley Online Library

NEURELIS PRESENTS STUDIES ON SEIZURE CLUSTERS AT THE AMERICAN EPILEPSY SOCIETY ANNUAL MEETING - PR Newswire

NEURELIS PRESENTS STUDIES ON SEIZURE CLUSTERS AT THE AMERICAN EPILEPSY SOCIETY ANNUAL MEETING PR Newswire

NEURELIS ENTERS $208 MILLION AGREEMENT TO MONETIZE INTRAVAIL ROYALTIES - PR Newswire

NEURELIS ENTERS $208 MILLION AGREEMENT TO MONETIZE INTRAVAIL ROYALTIES PR Newswire

NEURELIS SECURES NEW ORANGE BOOK LISTED U.S. PATENT FOR VALTOCO® (DIAZEPAM NASAL SPRAY) CIV - PR Newswire

NEURELIS SECURES NEW ORANGE BOOK LISTED U.S. PATENT FOR VALTOCO® (DIAZEPAM NASAL SPRAY) CIV PR Newswire

Neurelis Announces Commercial Availability of VALTOCO® (Diazepam Nasal Spray) for Seizure Cluster Rescue - PR Newswire

Neurelis Announces Commercial Availability of VALTOCO® (Diazepam Nasal Spray) for Seizure Cluster Rescue PR Newswire

Neurelis Files New Drug Application With The FDA For VALTOCO™ Nasal Spray, An Investigational Treatment For Pediatric, Adolescent And Adult Epilepsy Patients - PR Newswire

Neurelis Files New Drug Application With The FDA For VALTOCO™ Nasal Spray, An Investigational Treatment For Pediatric, Adolescent And Adult Epilepsy Patients PR Newswire

NEURELIS WINS 2023 PM360 PHARMA CHOICE MULTICHANNEL GOLD AWARD FOR 'GIVE SEIZURES THE SPRAYER' MARKETING CAMPAIGN - PR Newswire

NEURELIS WINS 2023 PM360 PHARMA CHOICE MULTICHANNEL GOLD AWARD FOR 'GIVE SEIZURES THE SPRAYER' MARKETING CAMPAIGN PR Newswire

Neurelis Announces National Wholesale And Retailer Chains And Independent Pharmacies Are Now Stocking VALTOCO® (Diazepam Nasal Spray) - PR Newswire

Neurelis Announces National Wholesale And Retailer Chains And Independent Pharmacies Are Now Stocking VALTOCO® (Diazepam Nasal Spray) PR Newswire

Neurelis Announces Close Of $114 Million Series D Financing Round To Advance Neuroscience Focus - PR Newswire

Neurelis Announces Close Of $114 Million Series D Financing Round To Advance Neuroscience Focus PR Newswire

Neurelis Announces Acquisition Of Aegis Therapeutics, A Leading Drug Delivery Technology Company - PR Newswire

Neurelis Announces Acquisition Of Aegis Therapeutics, A Leading Drug Delivery Technology Company PR Newswire

NEURELIS SIGNS EXCLUSIVE LICENSING AGREEMENT WITH ACULYS PHARMA FOR THE DEVELOPMENT AND COMMERCIALIZATION OF VALTOCO® (DIAZEPAM NASAL SPRAY) IN JAPAN AND THE ASIA-PACIFIC REGION - PR Newswire

NEURELIS SIGNS EXCLUSIVE LICENSING AGREEMENT WITH ACULYS PHARMA FOR THE DEVELOPMENT AND COMMERCIALIZATION OF VALTOCO® (DIAZEPAM NASAL SPRAY) IN JAPAN AND THE ASIA-PACIFIC REGION PR Newswire

Neurelis Announces That Intravail® Licensee, ARS Pharmaceuticals' Intranasal Epinephrine Product, Demonstrates Bioequivalent Exposure To Epinephrine Injectors - PR Newswire

Neurelis Announces That Intravail® Licensee, ARS Pharmaceuticals' Intranasal Epinephrine Product, Demonstrates Bioequivalent Exposure To Epinephrine Injectors PR Newswire

Rapid Administration of Diazepam Results in Improved Seizure Cluster Cessation, Shorter Seizures - NeurologyLive

Rapid Administration of Diazepam Results in Improved Seizure Cluster Cessation, Shorter Seizures NeurologyLive

Neurelis secures FDA approval for Valtoco to treat seizure clusters - World Pharmaceutical Frontiers

Neurelis secures FDA approval for Valtoco to treat seizure clusters World Pharmaceutical Frontiers

Current and Future Treatment Options for Cerebral Cavernous Malformations - American Heart Association Journals

Current and Future Treatment Options for Cerebral Cavernous Malformations American Heart Association Journals

Neurelis to Host Virtual Pipeline Update to Discuss Advancements Addressing Unmet Needs in Neuroscience on March 7, 2024 - BioSpace

Neurelis to Host Virtual Pipeline Update to Discuss Advancements Addressing Unmet Needs in Neuroscience on March 7, 2024 BioSpace

FDA accepts NDA for neffy intranasal epinephrine - Drug Delivery Business

FDA accepts NDA for neffy intranasal epinephrine Drug Delivery Business

Neurelis debuts seizure awareness campaign as it waits for FDA nod - Fierce Pharma

Neurelis debuts seizure awareness campaign as it waits for FDA nod Fierce Pharma

Nasal Spray Valtoco Approved for Seizure Clusters in Epileptics 6 and Older - Dravet Syndrome News

Nasal Spray Valtoco Approved for Seizure Clusters in Epileptics 6 and Older Dravet Syndrome News

eBook: Formulation, Fill, Finish ⁠— Biopharmaceutical Drug Products for a Modern Age - BioProcess International

eBook: Formulation, Fill, Finish ⁠— Biopharmaceutical Drug Products for a Modern Age BioProcess International

Top Neurelis, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant